FIELD: medicine.
SUBSTANCE: invention relates to an antibody-drug conjugate, wherein the antitumour compound represented by the formula:
is conjugated to the anti-TROP2 antibody through a thioether bond, which is formed on the disulphide bond section present in the hinge portion of the anti-TROP2 antibody, through a linker having a structure represented by -L1-L2-LP-NH-(CH2)n1-La-(CH2)n2-C(=O)-.
EFFECT: technical result is obtaining a novel conjugate for providing an antitumour drug exhibiting an excellent therapeutic effect, which is excellent in terms of antitumour effect and safety.
28 cl, 22 ex, 2 tbl, 27 dwg
Title | Year | Author | Number |
---|---|---|---|
ANTI-TROP2 ANTIBODY-DRUG CONJUGATE | 2014 |
|
RU2743077C2 |
ANTIBODY-DRUG CONJUGATE | 2013 |
|
RU2664465C2 |
ANTI-HER3 ANTIBODY-DRUG CONJUGATE | 2015 |
|
RU2711640C2 |
ANTIBODY-DRUG CONJUGATE | 2013 |
|
RU2776489C2 |
ANTI-HER3 CONJUGATE ANTIBODY-DRUG | 2015 |
|
RU2802211C2 |
ANTI-HER2 ANTIBODY-DRUG CONJUGATE | 2015 |
|
RU2683780C2 |
ANTI-HER2 ANTIBODY DRUG CONJUGATE | 2015 |
|
RU2794183C2 |
ANTI-MUC1 DRUG CONJUGATE | 2019 |
|
RU2804703C2 |
ANTI-CDH6-ANTIBODY AND ANTI-CDH6-ANTIBODY-DRUG CONJUGATE | 2018 |
|
RU2798285C2 |
ANTIBODY AGAINST GPR20 AND ANTIBODY AGAINST GPR20-DRUG CONJUGATES | 2018 |
|
RU2772804C2 |
Authors
Dates
2019-11-07—Published
2014-12-24—Filed